NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Researchers Present Over 110 Studies Enabled by NanoString Platforms, including the new GeoMx IO Proteome Atlas and 6K Discovery Panel on the CosMx SMI

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024.

NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms. The abstracts that will be featured include 14 studies exploring spatial biology using the CosMx™ Spatial Molecular Imager (SMI), 46 studies powered by GeoMx® Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter® Analysis System.

“NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today. These research contributions are changing our understanding of the underlying biology driving tumor growth and metastases, greatly accelerating the development of new therapeutic approaches,” said Joseph Beechem, Ph.D., Chief Scientific Officer and Senior Vice President of Research and Development, NanoString Technologies. “The spatial biology revolution has arrived! These new biological insights will help the field evolve from treating cancer to curing cancer.”

Nanostring Product Showcase in Theater B, April 9, 10:00-11:00 AM PT

• Dr. Beechem will present NanoString’s spatial biology roadmap and highlight recent advancements in a talk entitled "Highest-Plex Spatial Multi-Omics – Eliminating the Blind Spots in Your Research.” He will be joined by Arutha Kulasinghe, Ph. D. Senior Research Fellow and Leader of the Clinical-oMx Lab at the University of Queensland, who will speak on "Uncoupling pathways involved in immunotherapy resistance: insights from deep tissue profiling.”

Oral presentations:

• Sunday, April 7, 4:20-4:35 PM PT - Golnaz Morad, Ph. D., from MD Anderson Cancer Center will present, “Digital spatial profiling of metastatic brain tumors reveals association of the tumor microbiome with immune alterations in the tumor microenvironment.” This study investigated the role of distinct microbial communities in metastatic brain tumors through metagenomic sequencing of stool and saliva samples, 16S rRNA gene sequencing of tumor samples and spatial transcriptome and proteome analysis using NanoString platforms. The spatially resolved NanoString work was able to unequivocally resolve intracellular versus extracellular bacterial signals, greatly expanding our understanding of the innate-immune mediated anti-bacterial response within the tumor microenvironment.
• Monday, April 8, 4:05-4:20 PM PT - Jingyi Cao, Ph. D from Gene Lay Institute of Immunology and Inflammation, Brigham and Women’s Hospital and Harvard Medical School will present, “Therapy-associated remodeling of pancreatic cancer revealed by single-cell spatial transcriptomics and optimal transport analysis.” This study utilizes high-plex single-cell spatial molecular imaging (NanoString’s CosMx 1K Cell Characterization Panel) to dissect treatment-remodeled multicellular neighborhoods and malignant-stroma cell interactions in primary resected human pancreatic cancer. It revealed IL-6 family signaling as a potential inducer of chemoresistance.
• Tuesday, April 9, 3:50-4:05 PM PT - Isobelle Wall, Kings College London, will present, “Spatial transcriptomics delineates tumor heterogeneity in NACT triple-negative breast cancer.” This study utilizes spatial transcriptomics to investigate the histological and molecular heterogeneity of triple-negative breast cancer pre- and post-neoadjuvant chemotherapy. It revealed potential chemo-resistant properties and spatially distinct immune cell compositions associated with treatment response.

NanoString team members will welcome customers at booth 331.

About NanoString

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

For more information, visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

This news release may include information regarding CosMx™ SMI products for RNA detection, products that are not available in the Federal Republic of Germany. Such limitations are further described here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404548542/en/